GSK to buy 35Pharma for $950 million | ReutersSkip to main content[Exclusive news, data and analytics for financial market professionalsLearn more aboutRefinitiv]GSK (GlaxoSmithKline) logo is seen in this illustration, August 10, 2022. REUTERS/Dado Ruvic/Illustration [Purchase Licensing Rights, opens new tab]- Companies[GSK plc]FollowFeb 25 (Reuters) - GSK [(GSK.L), opens new tab] on Wednesday agreed to buy Canadian biopharmaceutical company 35Pharma Inc for $950 million in cash.Sign up [here.]Reporting by ...

Group 1 - Halper Sadeh LLC is investigating potential violations of federal securities laws and breaches of fiduciary duties related to the sale of Penumbra, Inc. to Boston Scientific Corporation for $374.00 in cash or 3.8721 shares of Boston Scientific common stock [1] - RAPT Therapeutics, Inc. is being investigated for its sale to GSK plc for $58.00 per share [2] - The firm may seek increased consideration for shareholders, additional disclosures, and other relief on behalf of shareholders, operating on a contingent fee basis [3] Group 2 - Shareholders are encouraged to contact Halper Sadeh LLC free of charge to discuss their legal rights and options [4] - Halper Sadeh LLC represents investors globally who have experienced securities fraud and corporate misconduct, recovering millions for defrauded investors [4]

Core Viewpoint - Rapt Therapeutics is making headlines due to its acquisition by GSK, which values the deal at approximately $2.2 billion, despite a recent downgrade in its stock rating from Guggenheim [1][2]. Group 1: Acquisition Details - GSK is acquiring Rapt Therapeutics for $58.00 per share, which represents a significant premium and values the total deal at around $2.2 billion [1][2]. - The acquisition involves an upfront investment of $1.9 billion net of cash acquired, allowing GSK to access RAPT's late-stage food allergy treatment, ozureprubart [2]. Group 2: Product Information - Ozureprubart is a long-acting anti-IgE monoclonal antibody currently in phase 2b clinical development, aimed at providing prophylactic protection against food allergens [2]. - This innovative drug targets IgE, a validated target in severe food allergies, and promises a more convenient treatment option compared to existing therapies that require frequent injections [2]. Group 3: Market Reaction and Legal Investigation - Following the acquisition announcement, RAPT's stock surged by 64%, reaching a new 52-week high of $57.61, with a market capitalization of approximately $951.3 million [1][3]. - Halper Sadeh LLC is investigating the fairness of the sale to ensure it aligns with the best interests of RAPT shareholders and whether the board of directors has fulfilled its responsibilities [3].

Core Viewpoint - Monteverde & Associates PC is investigating the proposed sale of RAPT Therapeutics, Inc. to GSK plc, where RAPT shareholders are expected to receive $58.00 in cash per share, raising questions about the fairness of the deal [1]. Group 1: Company Overview - Monteverde & Associates PC is recognized as a Top 50 Firm in the 2024 ISS Securities Class Action Services Report and has recovered millions for shareholders [1]. - The firm is located in the Empire State Building, New York City, and specializes in class action securities litigation [2]. Group 2: Transaction Details - The proposed transaction involves RAPT Therapeutics, Inc. selling to GSK plc, with shareholders set to receive $58.00 in cash for each share of RAPT common stock [1]. - The investigation aims to determine whether this transaction is fair for RAPT shareholders [1].

Core Viewpoint - Ademi LLP is investigating RAPT for potential breaches of fiduciary duty and other legal violations related to its transaction with GSK plc [1] Group 1: Transaction Details - RAPT stockholders can choose to receive $58.00 per share, leading to an estimated total equity value of $2.2 billion [2] - RAPT insiders are set to gain significant benefits from change of control arrangements as part of the transaction [2] Group 2: Investigation Focus - The transaction agreement restricts competing offers for RAPT by imposing a substantial penalty if a competing bid is accepted [3] - The investigation will assess whether the RAPT board of directors is meeting their fiduciary responsibilities to all shareholders [3]

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of RAPT Therapeutics, Inc. (NASDAQ: RAPT) to GSK plc for $58.00 per share is fair to RAPT shareholders. Halper Sadeh encourages RAPT shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or sadeh@halpersadeh.com or zhalper@halpersadeh.com. The investigation concerns whether RAPT and its board of directors violated th ...

Core Viewpoint - Mersana Therapeutics, Inc. has entered into a definitive merger agreement with Day One Biopharmaceuticals, Inc., which includes an upfront cash consideration of $25.00 per share and potential contingent value rights (CVRs) that could increase the total deal value to approximately $285 million, with closing expected by the end of January 2026 [2][9]. Business Update - Mersana is focused on developing antibody-drug conjugates (ADCs) for cancer treatment, particularly in areas with high unmet medical needs [1][12]. - The company is currently conducting Phase 1 clinical trials for its lead candidates, Emi-Le and XMT-2056, targeting specific cancer types [3][6]. Clinical Trials - The ongoing Phase 1 trial of Emi-Le is evaluating its efficacy in patients with triple-negative breast cancer (TNBC) and adenoid cystic carcinoma type 1 (ACC-1), with encouraging responses reported [3][4]. - Mersana has also achieved a $15 million development milestone related to XMT-2056 under its collaboration with GSK [6]. Financial Results - For Q3 2025, Mersana reported collaboration revenue of $11.0 million, a decrease from $12.6 million in Q3 2024, primarily due to reduced revenue from partnerships with Johnson & Johnson and Merck KGaA [15]. - The company incurred a net loss of $7.5 million, or $1.51 per share, compared to a net loss of $11.5 million, or $2.34 per share, in the same period last year [15][17]. - As of September 30, 2025, Mersana had cash and cash equivalents of $56.4 million, which is expected to support operations into mid-2026 [15].

Core Insights - Maze Therapeutics has appointed Misbah Tahir as Chief Financial Officer, effective immediately, during a critical phase for the company [1][2] - The company is preparing for significant milestones, including data releases for MZE782 and MZE829 in 2025 and 2026 [2] - Mr. Tahir brings over 20 years of experience in the biopharmaceutical industry, having previously served as CFO at IGM Biosciences and held senior finance roles at other notable companies [2][3] Company Overview - Maze Therapeutics is a clinical-stage biopharmaceutical company focused on developing small molecule precision medicines for kidney and metabolic diseases [4] - The company utilizes its Compass platform to pursue genetically validated targets, integrating variant discovery and functionalization [4] - Maze's pipeline includes MZE829, an oral APOL1 inhibitor in Phase 2 development, and MZE782, an oral SLC6A19 inhibitor in Phase 1, targeting chronic kidney disease and phenylketonuria [4] Financial Position - Maze Therapeutics has a strong balance sheet with an expected cash runway extending into the second half of 2027 [3] - The company aims to create significant value for patients and shareholders through its differentiated precision genetics platform and disciplined development approach [3]

周五（5月16日），阿斯麦控股荷兰阿姆斯特丹股价（ASML.NA）收跌2.02%，报668.40欧元，本周累计上涨6.64%。 诺和诺德哥本哈根股价（NOVOB.DC）收跌1.81%，报426.60（丹麦克朗），本周累跌4.00%。 | 名称 = | | 代码 = | | 开盘 | | | 涨跌额 : | 涨跌幅 : | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | GSK plc | | GSK | 1.394.50 | 1.388.50 | 1,403.50 | 1.380.50 | +32.00 | +2.35% | | | 赛诺菲 | SASY | 91.79 | 91.76 | 92.11 | 90.93 | +1.92 | +2.14% | | HE | 阿斯利康制药 | AZN | 10,330.0 | 10,230.0 | 10,376.0 | 10,214.2 | +188.0 | +1.85% | | I | SAP公司 | SAPG | 266.250 | 263.250 | 268.300 | 263.250 | + ...

| 名称 = | | 代码 = | 最新价 | 开盘 | 틀 | | 涨跌额 = | 涨跌幅 * | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 路易威登 | | LVMH | 530.50 | 509.00 | 536.40 | 508.30 | +34.75 | +7.01% | | II | 阿斯麦公司 | ASMIL | 666.90 | 640.00 | 668.20 | 639.30 | +40.10 | +6.40% | | 欧莱雅 | | OREP | 394.55 | 384.90 | 394.65 | 384.90 | +11.35 | +2.96% | | 赛诺菲 | | SASY | 91.14 | 87.27 | 91.14 | 87.00 | +2.14 | +2.40% | | + | 罗氏制药公司 | ROG | 261.90 | 247.70 | 262.10 | 246.00 | +4.30 | +1.67% | | 用品 | GSK plc | CSK | 1,399.50 | 1.340.00 | ...